FDA Marks New Era in Diabetes Care with First Dual Glucose-Ketone Wearable and OTC Pediatric CGM

September 13, 2026

FDA News / Health Technology News USA

Overview

The U.S. FDA has ushered in a new chapter for diabetes technology, authorizing Abbott’s Libre Duo as the first wearable device for continuous dual monitoring of glucose and ketones, and clearing Dexcom’s Stelo as the first over-the-counter (OTC) continuous glucose monitor (CGM) for pediatric use. These landmark approvals, addressing patients aged 2 and older, are set to significantly enhance early DKA risk detection and expand access to real-time, prescription-free monitoring, driving advancements in diabetes self-management and preventive care.

In Depth

Background

The continuous glucose monitoring (CGM) market has been undergoing rapid expansion, fueled by persistent demand for more miniaturized, accurate, and user-friendly devices. This trajectory aligns with a broader healthcare trend prioritizing patient empowerment and preventative care through accessible, real-time health data. The recent FDA authorizations are expected to accelerate these market dynamics, particularly benefiting individuals managing diabetes in diverse environments and expanding access for underserved populations seeking proactive health monitoring.

Key Approvals

On September 3, 2026, the U.S. Food and Drug Administration (FDA) announced two pivotal authorizations that are set to redefine diabetes management. First, Abbott’s Libre Duo received clearance as the inaugural wearable device capable of continuously monitoring both blood glucose and ketone levels. This 10-day sensor system is indicated for individuals aged 2 and above, marking a significant stride in the early detection and prevention of severe complications such as diabetic ketoacidosis (DKA). Concurrently, Dexcom’s Stelo Glucose Biosensor System secured clearance as the first over-the-counter (OTC) continuous glucose monitor (CGM) specifically for children aged 2 to 18, extending its prior authorization for adults over 18. These approvals collectively underscore a strategic pivot towards enhanced accessibility and comprehensive real-time physiological monitoring.

Technical Insights

Abbott’s Libre Duo leverages a compact, skin-worn electrochemical sensor designed to continuously measure glucose and ketone concentrations directly from interstitial fluid. The dual-analyte monitoring represents a significant technological leap, moving beyond sole glucose tracking to provide proactive alerts for ketone accumulation—a critical precursor to DKA, particularly relevant for individuals with type 1 diabetes. This innovation provides a more holistic view of metabolic state, enabling more nuanced clinical decision-making regarding insulin titration and lifestyle modifications. Similarly, Dexcom’s Stelo, now accessible OTC for pediatric populations, offers high-accuracy, real-time glucose trend visualization. By obviating the need for frequent finger-prick blood tests, Stelo facilitates continuous data streams crucial for dynamic diabetes management in active children, empowering parents and healthcare providers to implement timely and effective therapeutic strategies for improved long-term pediatric health outcomes.

Strategic Significance & Outlook

These regulatory advancements are poised to drive a transformative shift in diabetes care paradigms. The Libre Duo’s dual-monitoring capability is projected to significantly reduce DKA-related hospitalizations by facilitating earlier intervention, thereby improving public health outcomes and enabling more proactive disease management. The expanded availability of OTC CGMs, exemplified by Dexcom Stelo for children, will empower consumer-driven health initiatives, broadening access to preventative care and early disease intervention across demographics. The competitive landscape is expected to intensify as other manufacturers accelerate their dual-biomarker and OTC strategies, fostering accelerated innovation within the wearable biosensor industry. Looking ahead, the synergy of continuous sensor data with advanced AI and machine learning algorithms promises to unlock personalized treatment recommendations and predictive health alerts, heralding a new era of precision diabetes care. Continued advancements in device miniaturization, extended wear duration, and multi-functionality will further solidify the indispensable role of wearable biosensors in comprehensive chronic disease management and proactive health monitoring.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.